Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Perindopril
Drug ID BADD_D01739
Description Perindopril is a nonsulfhydryl prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly metabolized in the liver to perindoprilat, its active metabolite, following oral administration. Perindoprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Perindopril may be used to treat mild to moderate essential hypertension, mild to moderate congestive heart failure, and to reduce the cardiovascular risk of individuals with hypertension or post-myocardial infarction and stable coronary disease.
Indications and Usage For the treatment of mild to moderate essential hypertension, mild to moderate congestive heart failure, and to reduce the cardiovascular risk of individuals with hypertension or post-myocardial infarction and stable coronary disease.
Marketing Status Prescription; Discontinued
ATC Code C09AA04
DrugBank ID DB00790
KEGG ID D03753
MeSH ID D020913
PubChem ID 107807
TTD Drug ID D03KYG
NDC Product Code 65977-0019
Synonyms Perindopril | Pirindopril | S-9490 | S 9490 | S9490 | S 9490-3 | S 9490 3 | S 94903 | Perindopril Erbumine | Erbumine, Perindopril | Perstarium
Chemical Information
Molecular Formula C19H32N2O5
CAS Registry Number 82834-16-0
SMILES CCCC(C(=O)OCC)NC(C)C(=O)N1C2CCCCC2CC1C(=O)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Blood pressure decreasedAngiotensin-converting enzymeP12821T8257716395257; 16138565; 9270093; 10535720; 9726242; 10620209; 10880412; 8986921; 10999650
CoughB2 bradykinin receptorP30411T2371410904024; 12522467; 11699055; 15894833
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Diarrhoea07.02.01.001--
Discomfort08.01.08.003--Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Drug interaction08.06.03.001--Not Available
Dry mouth07.06.01.002--
Dry skin23.03.03.001--
Dysgeusia17.02.07.003; 07.14.03.001--
Dyspepsia07.01.02.001--
Dysphonia22.02.05.005; 19.19.03.002; 17.02.08.004--
Dyspnoea22.02.01.004; 02.01.03.002--
Ear infection11.01.05.001; 04.03.01.006--Not Available
Ear pain04.03.01.003--
Ecchymosis01.01.03.001; 24.07.06.002; 23.06.01.001--Not Available
Eczema23.03.04.006--
Electrocardiogram abnormal13.14.05.001--Not Available
Eosinophilia01.02.04.001--
Eosinophilic pneumonia22.01.01.004; 01.02.04.003--Not Available
Epistaxis22.04.03.001; 24.07.01.005--
Erythema23.03.06.001--Not Available
Eye disorder06.08.03.001--Not Available
Face oedema23.04.01.004; 10.01.05.002; 08.01.07.003--
Feeling abnormal08.01.09.014--Not Available
Flank pain08.01.08.007; 20.02.03.006; 15.03.04.003--
Flatulence07.01.04.002--
Fluid retention20.01.02.003; 14.05.06.002--Not Available
Flushing24.03.01.002; 23.06.05.003; 08.01.03.025--
Gastroenteritis11.01.07.004; 07.19.03.001--Not Available
Gastrointestinal disorder07.11.01.001--Not Available
Gastrointestinal pain07.01.05.005--
Gout15.01.06.001; 14.09.01.001--Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 6 Pages